For example, the MEK inhibitor selumetinib demonstrated activity in BRAF V600E-mutant, KIAA1549:BRAF fusion positive and NF1-mutant (lower grade) gliomas, providing a rationale for its evaluation in HGAP [12]. The gene discussed is BRAF; the disease is central nervous system cancer.